Astellas Pharma Korea
- A02 - Agentes para el tratamiento de alteraciones causadas por ácidos
- GASTER D film-coated tablet 20 mg
- A04 - Antieméticos y antinauseosos
- IRRIBOW tablet 2.5 µg
- IRRIBOW tablet 5 µg
- NASEA orodispersible tablet 100 µg
- NASEA solution for injection 300 µg
- A10 - Antidiabéticos
- SUGLAT tablet 50 mg
- D11 - Otros preparados dermatológicos
- PROTOPIC ointment 0.03%
- PROTOPIC ointment 0.1%
- G04 - Urológicos
- BETAMIGA prolonged-release tablet 25 mg
- BETAMIGA prolonged-release tablet 50 mg
- HAMAL D prolonged-release tablet 0.2 mg
- HARNAL D oral lyophilisate 0.2 mg
- HARNAL D tablet 0.2 mg
- VESICARE film-coated tablet 10 mg
- VESICARE film-coated tablet 5 mg
- H01 - Hormonas hipofisiarias, hipotalámicas y análogos
- DDAVP tablet 0.1 mg
- DDAVP tablet 0.2 mg
- J02 - Antimicóticos de uso sistémico
- MYCAMINE powder for solution for infusion 50 mg
- MYCAMINE powder for solution for infusion 50 mg
- L02 - Terapia endocrina
- EXTANDI capsule, soft 40 mg
- L04 - Inmunosupresores
- ADVAGRAF ASTELLAS prolonged-release capsule, hard 0.5 mg
- ADVAGRAF ASTELLAS prolonged-release capsule, hard 1 mg
- ADVAGRAF ASTELLAS prolonged-release capsule, hard 5 mg
- PROGRAF capsule, hard 0.5 mg
- PROGRAF capsule, hard 1 mg
- PROGRAF capsule, hard 5 mg
- PROGRAF concentrate for solution for infusion 5 mg/1 ml